Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Hsiao-Wei Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Urinary Tract Infections, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fu Jen Catholic University Hospital, Shin Kong Wu Ho-Su Memorial Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To evaluate whether initiating sodium‐glucose cotransporter 2 inhibitors (SGLT2i) within 3 months after a urinary tract infection (UTI) is associated with improved long‐term outcomes in patients with type 2 diabetes mellitus (T2DM), compared with dipeptidyl peptidase‐4 inhibitors (DPP‐4i). Materials and Methods A retrospective cohort study was conducted using the TriNetX US Collaborative Network (2016–2023). Adults with T2DM who initiated SGLT2i or DPP‐4i within 90 days after a UTI or pyelonephritis diagnosis were identified. Propensity score matching (1:1) was applied to balance baseline covariates. The primary outcome was mortality. Secondary outcomes included major adverse kidney events (MAKE), major adverse cardiovascular events (MACE), hospitalisation, dialysis dependence, emergency department (ED) visits, and sepsis. Outcomes were assessed over a 4‐year period using Cox proportional hazards models and Kaplan–Meier analysis.
Results
After matching, 2129 patients were included in each group. Compared with DPP‐4i, SGLT2i use was associated with lower risks of mortality (HR 0.59, 95% CI 0.45–0.77), MAKE (HR 0.78), hospitalisation (HR 0.89), dialysis dependence (HR 0.43), sepsis (HR 0.75), and ED visits (HR 0.88). No significant difference was found for MACE (HR 0.91, 95% CI 0.79–1.04).
Conclusions
In patients with T2DM recovering from UTI, the use of SGLT2 inhibitors was associated with lower risks of mortality, kidney complications, and infection‐related outcomes compared with DPP‐4 inhibitors. These findings support the safety and clinical benefit of continuing or initiating SGLT2i during the post‐infectious phase, even after a recent urinary tract infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Disease, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan.
- Division of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
- Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan.
ORCID-Profile: Ming-Hsien Tsai, Chien-Lin Lu
Förderung
- Fu Jen Catholic University Hospital
- Shin Kong Wu Ho-Su Memorial Hospital
Zitieren
APA
Wang, H. W., Tsai, M. H., Fang, Y. W., Lu, K. C., Wang, J., & Lu, C. L. (2025). Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70003
Vancouver
Wang HW, Tsai MH, Fang YW, Lu KC, Wang J, Lu CL. Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70003
BibTeX
@article{Wang2025,
author = {Wang, Hsiao-Wei and Tsai, Ming-Hsien and Fang, Yu-Wei and Lu, Kuo-Cheng and Wang, Joshua and Lu, Chien-Lin},
title = {Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70003}
}
EUVIMED